Work Here?
Overview
Causaly offers AI-powered tools for biomedical R&D that help pharmaceutical teams answer questions faster by analyzing vast scientific literature. The platform machine-reads content from over 40 million documents and builds a network of about 350 million directional relationships among diseases, pathways, and genes, presented in a visual interface that requires no specialized skills. It combines large-scale literature data with a human-centric AI approach to reduce reading time and speed up target and biomarker discovery. The goal is to accelerate drug discovery, shorten development timelines, lower costs, and improve the quality of decision-making in research.
About Causaly
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$82.7M
Headquarters
London, United Kingdom
Founded
2018
Get referred to Causaly
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 2026 Sage partnership expands evidence depth inside existing customer subscriptions.
- June 2026 Microsoft collaboration strengthens credibility with biopharma technical buyers.
- One top-50 pharma cut indication assessment from a month to days using Scientific Workflows.
What critics are saying
- Sage can revoke or reprice journal access, breaking Causaly evidence coverage quickly.
- Microsoft Discovery can commoditize Causaly’s workflow layer, squeezing pricing by 2027.
- Pharma consolidation and budget freezes slow renewals, punishing Causaly’s enterprise sales cycle.
What makes Causaly unique
- Causaly’s July 2026 Sage deal unlocks full-text reading across 400 journals.
- Microsoft Build 2026 integration ties Causaly reasoning to Discovery simulation workflows.
- Scientific Workflows, launched May 2026, turns biology methods into governed agentic execution.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$82.7M
Above
Industry Average
Funded Over
4 Rounds
Index VenturesIndustry standards
Benefits
Health Insurance
Dental Insurance
Life Insurance
Professional Development Budget
Wellness Program
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
Parental Leave
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 5%2 year growth
↑ 3%Sage Inks Publishing Deal with Causaly's AI Platform Focusing on Drug Discovery Research. July 29, 2026 San Francisco Biotechnology Network News News, Syndication Comments Off on Sage Inks Publishing Deal with Causaly's AI Platform Focusing on Drug Discovery Research In a new publishing deal, Causaly and Sage have announced a partnership to bring full-text scientific peer-reviewed literature into the world of AI-powered drug discovery research. According to Sage vice president Katie Metzler, who leads the publisher's global licensing team, this deal follows a similar partnership that Sage struck in January 2026 with Consensus, an AI workspace for scientific research based in San Francisco. The deal also marks Causaly's first partnership with a major STM publisher. "It's an example of a broader shift happening with AI agents reading the full text of journals and providing human researchers with the sections they need, showing them how ideas are connected via their knowledge graph, saving time over traditional search and discovery methods and driving new insights that they may never have found via a traditional lit review methods."
Causaly has partnered with Sage to integrate full-text access to over 400 life sciences journals into its AI-powered research platform. The partnership allows Causaly's AI agents to analyse complete articles from Sage and Mary Ann Liebert journals, including methods, results tables, and supporting data. The integration is available as an add-on to existing Causaly subscriptions. Customers with Sage subscriptions can link directly to full articles, whilst those without receive article snapshots and purchasing options. Causaly's platform runs AI-powered relevance analysis before any article access, helping researchers evaluate content value before purchasing. This aims to reduce wasted spending on irrelevant papers and accelerate research workflows. The partnership combines Causaly's biomedical knowledge graph with Sage's scientific literature to deliver evidence-backed insights within a single platform.
Causaly has announced a collaboration with Microsoft at Microsoft Build 2026 to integrate scientific computation with interpretation for life sciences research and development. The solution combines Microsoft Discovery's analytics and simulation capabilities with Causaly's knowledge-graph reasoning across scientific sources. The collaboration addresses a key bottleneck in biopharma R&D, where computational signals require manual synthesis and evidence gathering that can delay programmes by weeks or months. The integrated platform supports workflows including target identification, biomarker strategy, in silico prediction and safety assessment. "Drug discovery does not suffer from a lack of data. It suffers from a lack of trustworthy interpretation," said Yiannis Kiachopoulos, co-founder and CEO of Causaly. The solution aims to deliver faster iterations, higher-confidence decisions and outputs meeting scientific review and regulatory standards.
Causaly has launched Scientific Workflows, a solution that codifies biopharma research and development processes into AI-executed workflows. The platform transforms expert scientific methods into repeatable, autonomous processes that produce structured outputs including target assessments, indication exploration reports and safety dossiers. The London-based company's system uses multi-agent orchestration to execute entire R&D workflows whilst maintaining scientific rigour and governance. Users can implement ready-made workflows or develop customised solutions that encode their organisation's unique scientific processes and data. Early deployments show significant time savings. One top 50 pharmaceutical company reduced indication assessment research from a month to days after implementing the workflow. Causaly can integrate internal data through its Private Data feature, enabling decisions based on both internal and external scientific evidence.
LONDON, Sept. 16, 2025 - Causaly has unveiled Causaly Agentic Research, a breakthrough agentic AI platform purpose-built for life sciences research and development.
Causaly is Hiring for 6 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Causaly
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$82.7M
Headquarters
London, United Kingdom
Founded
2018
Causaly is Hiring for 6 Jobs on Simplify!
Find jobs on Simplify and start your career today